Health technology assessment and private payers' coverage of personalized medicine

Journal of Oncology Practice

Volumn 7, Issue 3 SUPPL., 2011, Pages

  Trosman, Julia R ^a   Van Bebber, Stephanie L ^a   Phillips, Kathryn A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE POLICY; HUMAN; HUMAN EXPERIMENT; INFORMATION RETRIEVAL; MEDICAL PRACTICE; MEDICAL TECHNOLOGY; NORMAL HUMAN; PERSONALIZED MEDICINE; PRIVATE HEALTH INSURANCE; SEMI STRUCTURED INTERVIEW;

EID: 80052708746     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000300     Document Type: Article

References (37)

1. International Network of Agencies of Health Technology Assessment: INAHTA glossary. http://www.inahta.org/HTA/Glossary/∫-Health-Technology-Assessment
2. Emanuel EJ, Fuchs VR, Garber AM: Essential elements of a technology and outcomes assessment initiative. JAMA 298:1323-1325, 2007 (Pubitemid 47443345)
3. Sullivan SD, Watkins J, Sweet B, et al: Health technology assessment in healthcare decisions in the United States. Value Health 12:S39-S44, 2009 (suppl 2)
4. Fuchs VR: The proposed government health insurance company-no substitute for real reform. N Engl J Med 360:2273-2275, 2009
5. Department of Health and Human Services: Coverage and reimbursement of genetic tests and services: Report of the Secretary's advisory committee on genetics, health, and society. http://oba.od.nih.gov/oba/sacghs/reports/CR- report.pdf
6. President's Council of Advisors on Science and Technology: Priorities for personalized medicine. http://www.whitehouse.gov/files/documents/ostp/PCAST/ pcast-report-v2.pdf
7. Aspinall MG, Hamermesh RG: Realizing the promise of personalized medicine. Harv Bus Rev 85:108-117, 165, 2007
8. Deverka PA: Pharmacogenomics, evidence, and the role of payers. Public Health Genomics 12:149-157, 2009
9. Faulkner E: Clinical Utility or Impossibility? Addressing the molecular diagnostics health technology assessment and reimbursement conundrum. J Managed Care Med 12:42-55, 2010
10. Bhasker CR, Hardiman G: Advances in pharmacogenomics technologies. Pharmacogenomics 11:481-485, 2010
11. Agency for Healthcare Research and Quality: Update on horizon scans of genetic tests currently available for clinical use in cancers. Agency for Healthcare Research and Quality, Rockville, MD, November 3, 2010
12. Phillips KA: Closing the evidence gap in the use of emerging testing technologies in clinical practice. JAMA 300:2542-2544, 2008
13. Khoury MJ, Berg A, Coates R, et al: The evidence dilemma in genomic medicine. Health Aff (Millwood) 27:1600-1611, 2008
14. Somerfield MR, Einhaus K, Hagerty KL, et al: American Society of Clinical Oncology clinical practice guidelines: Opportunities and challenges. J Clin Oncol 26:4022-4026, 2008
15. Health Plan Enrollment: Market Share Data-Top 25 U.S. Health Plans, Ranked by Total Medical Enrollment. Atlantic Information Services, Washington, DC, 2009
16. BlueCross BlueShield Association: Technology evaluation center. http://www.bcbs.com/blueresources/tec/
17. ECRI Institute. https://www.ecri.org
18. Evaluation of Genomic Applications in Practice and Prevention. http://www.egappreviews.org
19. Hayes. http://www.hayesinc.com
20. Institute for Clinical and Economic Review. http://www.icer-review.org/
21. Department of Health and Human Services: United States Preventive Services Task Force. http://www.ahrq.gov/clinic/uspstfix.htm
22. UpToDate. http://www.uptodate.com
23. Neumann PJ: Lessons for health technology assessment: It is not only about the evidence. Value Health 12:S45-S48, 2009 (suppl 2)
24. Jönsson B: Health technology assessment: Regulators or payers-who will take the lead? Clin Ther 30:960-963, 2008
25. Trosman JR, Van Bebber SL, Phillips KA: Coverage policy development for personalized medicine: Private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract 6:238-242, 2010
26. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group: Recommendations from the EGAPP Working Group: Can tumor gene expression profiling improve outcomes in patients with breast cancer? Genet Med 11:66-73, 2009
27. CIGNA: CIGNA medical coverage policies. http://www.cigna.com/customer- care/healthcare-professional/coverage-positions/medical/mm-0298- coveragepositioncriteria-assay-genetic-expr-breast-cancer-patients.pdf
28. Empire Blue Cross Blue Shield: Medical coverage policies. http://www.empireblue.com/medicalpolicies/policies/mp-pw-a049879.htm
29. Meckley LM, Neumann PJ: Personalized medicine: Factors influencing reimbursement. Health Policy 94:91-100, 2010
30. Steiner CA, Powe NR, Anderson GF, et al: Technology coverage decisions by health care plans and considerations by medical directors. Med Care 35:472-489, 1997 (Pubitemid 127455046)
31. Teutsch SM, Bradley LA, Palomaki GE, et al: The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: Methods of the EGAPP Working Group. Genet Med 11:3-14, 2009
32. Neumann PJ, Palmer JA, Daniels N, et al: A strategic plan for integrating cost-effectiveness analysis into the US healthcare system. Am J Manag Care 14:185-188, 2008 (Pubitemid 351501856)
33. Conti R, Veenstra DL, Armstrong K, et al: Personalized medicine and genomics: Challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making 30:328-340, 2010
34. Bennett CL, Somerfield MR, Pfister DG, et al: Perspectives on the value of American Society of Clinical Oncology clinical guidelines as reported by oncologists and health maintenance organizations. J Clin Oncol 21:937-941, 2003 (Pubitemid 46606456)
35. Lyman GH: ASCO clinical practice guidelines: Past, present and future. J Oncol Pract 4:236-237, 2008
36. Fuchs VR: Four health care reforms for 2009. N Engl J Med 361:1720-1722, 2009
37. Draborg E, Gyrd-Hansen D, et al: International comparison of the definition and the practical application of health technology assessment. Int J Technol Assess Health Care 21:89-95, 2005 (Pubitemid 40229373)